Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I

被引:42
作者
Villani, P
Maserati, R
Regazzi, MB
Giacchino, R
Lori, F
机构
[1] POLICLIN SAN MATTEO,IRCCS,DEPT PHARMACOL,I-27100 PAVIA,ITALY
[2] POLICLIN SAN MATTEO,IRCCS,DEPT INFECT DIS,I-27100 PAVIA,ITALY
[3] POLICLIN SAN MATTEO,IRCCS,RES INST GENET & HUMAN THERAPY,I-27100 PAVIA,ITALY
关键词
D O I
10.1002/j.1552-4604.1996.tb04176.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a prospective, randomized, controlled, three-arm study, the pharmacokinetics of hydroxyurea administered as an antiviral agent in patients infected with human immunodeficiency virus type 1 (HIV-1) were evaluated. The three arms of the study consisted of azidothymidine (AZT) 250 mg twice daily, hydroxyurea 500 mg twice daily, or a combination of the two. Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis. Sample collection was performed at steady-state conditions and serum concentration-time data for hydroxyurea were fitted using a one-compartment model. Mean (+/- standard deviation) peak concentration (C-max) was 0.135 +/- 0.06 mmol/L and mean trough level (C-min) was 0.0085 +/- 0.003 mmol/L. Mean concentration at steady state was 0.045 +/- 0.006 mmol/L. Apparent clearance (Cl/F) was 0.18 +/- 0.005 L/hr/kg, and half-life (t(1/2)) was 2.5 +/- 0.5 hours, Hydroxyurea given orally to patients infected with HIV-1 was well absorbed from the gastrointestinal tract, with a t(max) of 0.85 to 0.96 hours after ingestion. Serum levels of hydroxyurea ranged from 0.01 to 0.13 mmol/L. These values are similar to the concentrations (between 0.01 and 0.1 mmol/L) demonstrated to inhibit HIV-1 in vitro. Our data show that hydroxyurea given at a dosage of 500 mg twice daily is sufficient to yield serum concentrations potentially useful for in vivo inhibition of HIV-1.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 14 条
[1]  
BELT RJ, 1980, CANCER, V46, P455, DOI 10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO
[2]  
2-N
[3]   EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA [J].
CHARACHE, S ;
TERRIN, ML ;
MOORE, RD ;
DOVER, GJ ;
BARTON, FB ;
ECKERT, SV ;
MCMAHON, RP ;
BONDS, DR ;
ORRINGER, E ;
JONES, S ;
STRAYHORN, D ;
ROSSE, W ;
PHILLIPS, G ;
PEACE, D ;
JOHNSONTELFAIR, A ;
MILNER, P ;
KUTLAR, A ;
TRACY, A ;
BALLAS, SK ;
ALLEN, GE ;
MOSHANG, J ;
SCOTT, B ;
STEINBERG, M ;
ANDERSON, A ;
SABAHI, V ;
PEGELOW, C ;
TEMPLE, D ;
CASE, E ;
HARRELL, R ;
CHILDERIE, S ;
EMBURY, S ;
SCHMIDT, B ;
DAVIES, D ;
KOSHY, M ;
TALISCHYZAHED, N ;
DORN, L ;
PENDARVIS, G ;
MCGEE, M ;
TELFER, M ;
DAVIS, A ;
CASTRO, O ;
FINKE, H ;
PERLIN, E ;
SITEMAN, J ;
GASCON, P ;
DIPAOLO, P ;
GARGIULO, S ;
ECKMAN, J ;
BAILEY, JH ;
PLATT, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1317-1322
[4]   HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].
CORTELAZZO, S ;
FINAZZI, G ;
RUGGERI, M ;
VESTRI, O ;
GALLI, M ;
RODEGHIERO, F ;
BARBUI, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136
[5]  
DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11
[6]  
GAO WY, 1994, MOL PHARMACOL, V46, P767
[7]  
GAO WY, 1993, P NATL ACAD SCI USA, V90, P892
[8]   DETERMINATION BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF HYDROXYUREA IN HUMAN PLASMA [J].
HAVARD, J ;
GRYGIEL, J ;
SAMPSON, D .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 584 (02) :270-274
[9]   HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION [J].
LORI, F ;
MALYKH, A ;
CARA, A ;
SUN, D ;
WEINSTEIN, JN ;
LISZIEWICZ, J ;
GALLO, RC .
SCIENCE, 1994, 266 (5186) :801-805
[10]   SUPPRESSION OF HIV PRODUCTION IN RESTING LYMPHOCYTES BY COMBINING DIDANOSINE AND HYDROXAMATE COMPOUNDS [J].
MALLEY, SD ;
GRANGE, JM ;
HAMEDISANGSARI, F ;
VILA, JR .
LANCET, 1994, 343 (8908) :1292-1292